Quote:
Originally Posted by hopeful
is there a pharm company behind this research? I'm not sure if NIH gets their money for research from pharm companies.
|
It looks to me like a study of (or on)
Sativex® (nabiximols), which came up earlier in this thread. Use the
Search this Thread function (upper right under the page numbers).
From the study:
Quote:
The efficacy of Δ(9) -tetrahydrocannabinol/cannabidiol (THC/CBD) oromucosal spray, a novel cannabinoid formulation, was investigated in this 15-week randomized, double-blind, placebo-controlled parallel group study.
http://www.ncbi.nlm.nih.gov/pubmed/24420962
|
About Sativex® (nabiximols):
Quote:
Nabiximols (USAN,[1] trade name Sativex) is a patented cannabinoid oromucosal mouth spray developed by the UK company GW Pharmaceuticals for multiple sclerosis (MS) patients, who can use it to alleviate neuropathic pain, spasticity, overactive bladder, and other symptoms.[2] Nabiximols is distinct from all other pharmaceutically produced cannabinoids currently available because it is a mixture of compounds derived from Cannabis plants, rather than a mono-molecular synthetic product. The drug is a pharmaceutical product standardised in composition, formulation, and dose, although it is still effectively a tincture of the cannabis plant. Its principal active cannabinoid components are the cannabinoids: tetrahydrocannabinol (THC) and cannabidiol (CBD). The product is formulated as an oromucosal spray which is administered by spraying into the mouth. Each spray delivers a near 1:1 ratio of CBD to THC, with a fixed dose of 2.7 mg THC and 2.5 mg CBD. Nabiximols is also being developed in Phase III trials as a potential treatment to alleviate pain due to cancer. It has also been researched in various models of peripheral and central neuropathic pain.
http://en.wikipedia.org/wiki/Nabiximols
|
Doc